{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:22:35Z","timestamp":1785424955378,"version":"3.56.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"12","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA103528"],"award-info":[{"award-number":["R21 CA103528"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA44579"],"award-info":[{"award-number":["P30 CA44579"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["M01 RR00847"],"award-info":[{"award-number":["M01 RR00847"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>We report the long-term clinical outcomes of a multicenter, randomized phase II trial (NCT00089193) that tested immunogenicity of a vaccine composed of 12 class I MHC\u2013restricted melanoma peptides (12MP), with or without granulocyte\u2013macrophage colony\u2013stimulating factor (GM-CSF) as an adjuvant and administered at one or two sites in patients with resected high-risk melanoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Participants were randomized to one of four treatment arms: 12MP at one site (arm A), 12MP + GM-CSF at one site (arm B), 12MP at two sites (arm C), and 12MP + GM-CSF at two sites (arm D). The trial was powered to detect differences in immunogenicity by vaccine groups defined by GM-CSF status (arms B + D vs. A + C) and vaccine sites (arms A + B vs. C + D). For this analysis, overall survival (OS) and recurrence-free survival (RFS) were evaluated by these vaccine groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All eligible participants (n = 121) were evaluated. The median follow-up was 5.6 years. No significant differences in RFS or OS were observed by GM-CSF status. Participants vaccinated at two sites compared with one had significantly improved RFS [hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.38\u20130.93; P = 0.02] and a trend to improved OS (HR, 0.64; 95% CI, 0.39\u20131.06; P = 0.08). On landmark multivariable analysis, two-site vaccination was the only significant predictor of RFS (HR, 0.55; 95% CI, 0.34\u20130.88; P = 0.01) after adjusting for CD8+ T-cell response and other prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results challenge the use of GM-CSF as a local vaccine adjuvant and support two-site vaccination. Future work to characterize the locoregional immune response to cancer vaccination at the injection site and vaccine-draining lymph nodes is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1078-0432.ccr-25-4606","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:57:58Z","timestamp":1773853078000},"page":"2381-2390","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of GM-CSF and Two-Site Vaccination on Clinical Outcomes after Multipeptide Vaccination for Melanoma: Long-term Analysis of a Randomized Phase II Trial"],"prefix":"10.1158","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2973-9883","authenticated-orcid":false,"given":"Emily K.","family":"Ninmer","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 1 Division of Surgical Oncology, Department of Surgery; and the Human Immune Therapy Center, University of Virginia Comprehensive Cancer Center at the , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-3351","authenticated-orcid":false,"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 2 Division of Biostatistics, Department of Public Health Sciences, , Charlottesville, Virginia."},{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 3 University of Virginia Comprehensive Cancer Center, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-4281","authenticated-orcid":false,"given":"Amrita","family":"Sarkar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 1 Division of Surgical Oncology, Department of Surgery; and the Human Immune Therapy Center, University of Virginia Comprehensive Cancer Center at the , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-3671","authenticated-orcid":false,"given":"Kimberly A.","family":"Chianese-Bullock","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 1 Division of Surgical Oncology, Department of Surgery; and the Human Immune Therapy Center, University of Virginia Comprehensive Cancer Center at the , Charlottesville, Virginia."},{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 3 University of Virginia Comprehensive Cancer Center, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-0421","authenticated-orcid":false,"given":"Merrick I.","family":"Ross","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04twxam07","id-type":"ROR","asserted-by":"publisher"}],"name":"The University of Texas MD Anderson Cancer Center 4 Department of Surgical Oncology, , Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-7968","authenticated-orcid":false,"given":"Naomi B.","family":"Haas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00b30xv10","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Pennsylvania 5 Division of Hematology\/Oncology, Department of Medicine, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-890X","authenticated-orcid":false,"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 6 Department of Hematology\/Oncology, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2858-199X","authenticated-orcid":false,"given":"Marc E.","family":"Boisvert","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05ry42w04","id-type":"ROR","asserted-by":"publisher"}],"name":"MedStar Washington Hospital Center 7 Department of Surgery, , Washington, District of Columbia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3570-4476","authenticated-orcid":false,"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Medical Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-4373","authenticated-orcid":false,"suffix":"Jr","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 1 Division of Surgical Oncology, Department of Surgery; and the Human Immune Therapy Center, University of Virginia Comprehensive Cancer Center at the , Charlottesville, Virginia."},{"id":[{"id":"https:\/\/ror.org\/0153tk833","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Virginia 3 University of Virginia Comprehensive Cancer Center, , Charlottesville, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026061503120270700_bib1","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.1038\/s41598-017-08665-9","article-title":"Enhancing immune responses to cancer vaccines using multi-site injections","volume":"7","author":"Mould","year":"2017","journal-title":"Sci Rep"},{"key":"2026061503120270700_bib2","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2007.13.9048","article-title":"Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor","volume":"26","author":"Daud","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026061503120270700_bib3","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1158\/0008-5472.CAN-12-4124","article-title":"GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-\u03b1","volume":"73","author":"Kohanbash","year":"2013","journal-title":"Cancer Res"},{"key":"2026061503120270700_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1189\/jlb.0310154","article-title":"GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms","volume":"89","author":"Bhattacharya","year":"2011","journal-title":"J Leukoc Biol"},{"key":"2026061503120270700_bib5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/annonc\/mdl158","article-title":"Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients","volume":"18","author":"Parmiani","year":"2007","journal-title":"Ann Oncol"},{"key":"2026061503120270700_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2051-1426-2-11","article-title":"Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma","volume":"2","author":"Kaufman","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2026061503120270700_bib7","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-016-1860-3","article-title":"Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma","volume":"65","author":"Hoeller","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2026061503120270700_bib8","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100(280\u2013288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2026061503120270700_bib9","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","article-title":"Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting","volume":"13","author":"Slingluff","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026061503120270700_bib10","doi-asserted-by":"crossref","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","article-title":"Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial","volume":"15","author":"Slingluff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026061503120270700_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/2326-6066.CIR-13-0084","article-title":"Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells","volume":"1","author":"Clancy-Thompson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2026061503120270700_bib12","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-08-2281","article-title":"Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment","volume":"69","author":"Harlin","year":"2009","journal-title":"Cancer Res"},{"key":"2026061503120270700_bib13","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1038\/ncomms8458","article-title":"Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat Commun"},{"key":"2026061503120270700_bib14","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1158\/0008-5472.CAN-04-2059","article-title":"CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease","volume":"64","author":"Mullins","year":"2004","journal-title":"Cancer Res"},{"key":"2026061503120270700_bib15","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","article-title":"Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy","volume":"50","author":"Chow","year":"2019","journal-title":"Immunity"},{"key":"2026061503120270700_bib16","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/bjc.2013.557","article-title":"CXCR3\/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2","volume":"109","author":"Bedognetti","year":"2013","journal-title":"Br J Cancer"},{"key":"2026061503120270700_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat Med"},{"key":"2026061503120270700_bib18","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","article-title":"CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity","volume":"56","author":"Moreno Ayala","year":"2023","journal-title":"Immunity"},{"key":"2026061503120270700_bib19","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"2026061503120270700_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2026061503120270700_bib21","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026061503120270700_bib22","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","article-title":"Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and\/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)","volume":"33","author":"Lawson","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026061503120270700_bib23","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-16-3016","article-title":"Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697)","volume":"23","author":"Butterfield","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026061503120270700_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1084\/jem.20021348","article-title":"Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control","volume":"198","author":"Mullins","year":"2003","journal-title":"J Exp Med"},{"key":"2026061503120270700_bib25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"2026061503120270700_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"2026061503120270700_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"2026061503120270700_bib28","doi-asserted-by":"crossref","first-page":"e004709","DOI":"10.1136\/jitc-2022-004709","article-title":"Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer","volume":"10","author":"Melssen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026061503120270700_bib29","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00262-013-1435-5","article-title":"Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund\u2019s adjuvant, with or without peptide","volume":"62","author":"Salerno","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2026061503120270700_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s40425-019-0625-x","article-title":"A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund\u2019s adjuvant in melanoma patients","volume":"7","author":"Melssen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026061503120270700_bib31","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1016\/j.cell.2021.08.020","article-title":"Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors","volume":"184","author":"Burger","year":"2021","journal-title":"Cell"},{"key":"2026061503120270700_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-07-1881","article-title":"Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity","volume":"14","author":"Kenter","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026061503120270700_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","article-title":"A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results","volume":"30","author":"Rappaport","year":"2024","journal-title":"Nat Med"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-4606\/3748790\/ccr-25-4606.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-25-4606\/3781834\/ccr-25-4606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/32\/12\/2381\/3802166\/ccr-25-4606.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/32\/12\/2381\/3802166\/ccr-25-4606.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:12:12Z","timestamp":1781507532000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/32\/12\/2381\/785692\/Impact-of-GM-CSF-and-Two-Site-Vaccination-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-4606","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1078-0432.32675019","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675025","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675037","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675016","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675049","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675028","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675043","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675022","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675055","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675034","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675013","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675046","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675040","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675052","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1078-0432.32675031","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1078-0432.c.8536767","asserted-by":"object"}]},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}